12:11 19/12/2014 Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug
Pfizer (PFE) Reports Positive Phase III Results For Nerve-Pain Drug
Bidness ETC - 13 hours ago
Pfizer Inc. (NYSE:PFE) yesterday announced positive results for its Phase III study evaluating pregabalin controlled-release (CR) treatment, marketed as Lyrica, as a treatment for postherpetic neuralgia, or pain due to nerve damage.
Stock Update: Pfizer Inc. (NYSE:PFE) - Street Report
Pfizer Is A Great Income Stock On A Pullback (PFE) - Seeking Alpha

12:11 19/12/2014 3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.
3 Pharma Giants Growing Significantly Faster Than Pfizer, Inc.
Motley Fool - 13 hours ago
The largest pharmaceutical company in the world, Pfizer (NYSE: PFE ) , is a fixture in a number of retirement portfolios, and it's a staple holding of income investors looking for exposure to the healthcare sector.

23:03 18/12/2014 Pfizers Duchenne Muscular Dystrophy Drug in Phase II
Pfizers Duchenne Muscular Dystrophy Drug in Phase II
Zacks.com - Dec 18, 2014
Pfizer Inc. (PFE - Analyst Report) enrolled the first patient in a multicenter phase II study on its experimental Duchenne muscular dystrophy (DMD) treatment, PF-06252616.
Pfizer Initiates Phase 2 Study of PF-06252616 in Duchenne Muscular Dystrophy - Business Wire (press release)
Pfizer starts phase 2 trial of PF-06252616 to treat patients with duchenne ... - pharmabiz.com

12:56 17/12/2014 Pfizer, Inc. Invests in Growth... Literally
Pfizer, Inc. Invests in Growth... Literally
Motley Fool - Dec 17, 2014
Pfizer Inc. (NYSE: PFE ) locked up commercial rights to Opko Health's (NYSE: OPK ) long-lasting human growth hormone in a deal worth hundreds of millions of dollars.

15:11 16/12/2014 Pfizer (PFE) Enters Licensing Agreement With Opko (OPK)
Pfizer (PFE) Enters Licensing Agreement With Opko (OPK)
Bidness ETC - Dec 16, 2014
Pfizer Inc. (NYSE:PFE) announced on Monday that it has inked a licensing agreement with Opko Health Inc. (NYSE:OPK) over the latter's long-acting human growth hormone (hGH-CTP).

12:56 11/12/2014 3 Reasons Pfizer, Inc. Could Soar in 2015
3 Reasons Pfizer, Inc. Could Soar in 2015
Motley Fool - Dec 11, 2014
Considering what a strong year it's been for health care stocks, especially biotech and pharmaceutical companies, Pfizer's (NYSE: PFE ) 7% year-to-date gains might leave a lot to be desired among shareholders. Pfizer struggled in 2014, as it has in ...

12:52 08/12/2014 Will Pfizer Inc End Up Buying Bristol-Myers Squibb As Its Interest In ...
Will Pfizer Inc End Up Buying Bristol-Myers Squibb As Its Interest In ...
Bidness ETC - Dec 8, 2014
Mergers and acquisitions (M&A)-related activity in the healthcare sector this year appears to be never-ending. Word on the Street now is that Pfizer Inc. (NYSE:PFE) may be looking into acquiring its New York-based neighbor, Bristol-Myers Squibb Co ...

7:31 08/12/2014 iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for ...
iTeos Therapeutics Announces License and Collaboration with Pfizer Inc. for ...
MarketWatch - Dec 8, 2014
GOSSELIES, Belgium, Dec. 8, 2014 /PRNewswire/ -- iTeos Therapeutics SA announced today a strategic collaboration with Pfizer Inc. pursuant to which iTeos will license to Pfizer rights to iTeos' pre-clinical compounds targeting Indoleamine 2,3 ...
Latest Top News Stories: Avanir Pharmaceuticals Inc (NASDAQ:AVNR), Pfizer ... - Markets Emerging

12:56 01/12/2014 Bristol-Myers Squibb and Pfizer Inc.'s Bet on This Small Biotech Stock Could ...
Bristol-Myers Squibb and Pfizer Inc.'s Bet on This Small Biotech Stock Could ...
Motley Fool - Dec 1, 2014
Last week, Portola Pharmaceuticals (NASDAQ: PTLA ) reported interim results from a phase 3 trial of its drug andexanet alfa at the American Heart Association's Scientific Sessions 2014 conference -- results that could have big implications on Bristol ...

13:15 26/11/2014 5 Things Pfizer, Inc.'s Management Wants You to Know
5 Things Pfizer, Inc.'s Management Wants You to Know
Motley Fool - Nov 26, 2014
Pharmaceutical behemoth Pfizer (NYSE: PFE ) delivered its third-quarter earnings report late last month and all things considered it was pretty much in-line with Wall Street's expectations.